Analyst Expectations for Avadel Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Avadel Pharmaceuticals (NASDAQ:AVDL) has received positive analyst ratings in the last quarter, with 8 bullish and 5 somewhat bullish ratings. The average 12-month price target for the company is $17.88, which has increased by 10.3% over the past month.
June 30, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive analyst ratings and an increased price target suggest a bullish outlook for Avadel Pharmaceuticals.
Analyst ratings are a key indicator of a stock's potential performance. The positive ratings and increased price target for Avadel Pharmaceuticals suggest that analysts believe the company's stock will perform well in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100